{"id":"olmesartan-medoxomil-and-a-diuretic","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hypokalemia (diuretic component)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing vasoconstriction and aldosterone secretion. The addition of a diuretic (typically hydrochlorothiazide) increases renal sodium and water excretion, reducing circulating blood volume. Together, these complementary mechanisms provide synergistic antihypertensive effects.","oneSentence":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while the diuretic component enhances sodium and water excretion to further reduce fluid volume and blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:13.581Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT04185857","phase":"","title":"MRA and ARB Treatment in Screening of Primary Aldosteronism","status":"COMPLETED","sponsor":"University Hospital Padova","startDate":"2018-01-01","conditions":"Primary Aldosteronism Due to Aldosterone Producing Adenoma","enrollment":50},{"nctId":"NCT03560804","phase":"NA","title":"Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2014-11-10","conditions":"Arterial Stiffness, Ambulatory Blood Pressure Monitoring","enrollment":60},{"nctId":"NCT00858702","phase":"PHASE4","title":"Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2005-02","conditions":"Hypertension","enrollment":105},{"nctId":"NCT00834600","phase":"NA","title":"Renin Profiling in Selection of Initial Antihypertensive Drug","status":"COMPLETED","sponsor":"The Louis & Rachel Rudin Foundation","startDate":"2005-12","conditions":"Hypertension","enrollment":185},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00607035","phase":"PHASE4","title":"The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)","status":"COMPLETED","sponsor":"Jichi Medical University","startDate":"2006-05","conditions":"Hypertension","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"olmesartan medoxomil and a diuretic","genericName":"olmesartan medoxomil and a diuretic","companyName":"Daiichi Sankyo Co., Ltd.","companyId":"daiichi-sankyo-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while the diuretic component enhances sodium and water excretion to further reduce fluid volume and blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}